Corporate Magazine 2012 - Boehringer Ingelheim

esearch & developmentperspectives for medical innovationIDIOPATHIC PULMONARY FIBROSISIdiopathic pulmonary fibrosis results in a progressiveloss of lung function, associated with aclear deterioration in quality of life for patients.There is a high unmet need for effective newtreatments which may substantially change theclinical course of this deadly disease. Importantgoals are to influence the deterioration inlung function and to reduce the rate of exacerbations.normalipfO 2O 2O 2O 2O 2OO 22O 2O 2AFFECTS AS MANY AS14-43out of100,000PEOPLEcommon symptomsAnd is seen morefrequently in men.Resultant scarring/honeycombingin the lung restricts breathing andoxygen exchange.shortnessof breathchronicdry coughfingerclubbingTiotropium + olodaterol for COPDThe TOviTO phase III trial programmeis evaluating the potential benefits oftiotropium and olodaterol in a oncedailyfixed-dose combination using therespimat® Soft Mist Inhaler (SMI) device.The pivotal one-year registrationprogrammes for tiotropium and olodaterolfixed-dose combination are ontrack, with expected publication of resultsin 2014.Olodaterol is a complementary bronchodilatorthat has been studied extensivelyand developed as an ideal partnerto tiotropium in order to provide maximumbrochodilation for COPD patients.The scheduled announcement of thephase III clinical trial results for olodaterolis scheduled for 2013.options available to date. Approximately50% of patients with IPF die fromthe disease within two to five years afterdiagnosis. There is a high unmet clinicalneed for effective licensed agents.Phase II data from the TOMORROWtrial show that nintedanib 150 mg bidhas the potential to reduce disease progressionby slowing the annual declineof lung function, reducing acute exacerbationsand preserving quality of life.Nintedanib is currently in phase IIIclinical development. Two identicaltrials (INPULSIS-1 and INPULSIS-2)have been initiated and the last patientwas included in September 2012. Thistrial is being carried out in 24 countriesin Europe, the Americas, Asia andAustralia.NINTEDANIB IN IPFNintedanib is an investigationalsmall molecule tyrosine kinaseinhibitor (TKI) in development forIPF. It targets the growth factors:the vascular endothelial growthfactor receptor (VEGFR), fibroblastgrowth factor receptor (FGFR) andplatelet-derived growth factor receptor(PDGFR). These receptorshave been shown to be potentiallyinvolved in pathomechanismsof pulmonary fibrosis. By blockingthese signalling pathways that areinvolved in fibrotic processes, it isbelieved that nintedanib has thepotential to reduce disease progression,slowing the decline oflung function.Nintedanib in idiopathicpulmonary fibrosisIdiopathic pulmonary fibrosis (IPF) is aprogressive and severely debilitatinglung disease with high mortality, forwhich there are only limited treatmentMoving respiratory forward59